Abstract
In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Current Topics in Medicinal Chemistry
Title:Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union
Volume: 18 Issue: 25
Author(s): Aliuska Duardo-Sánchez*Iñigo De Miguel Beriain
Affiliation:
- Department of Public Law, Chair in Law and Human Genome Research Group, University of the Basque Country UPV/EHU, 48940, Leioa, Biscay,Spain
Keywords: Personalized medicine, Medicinal chemistry, Legal issues, Genomics, Data protection, Clinical trials.
Abstract: In the last few years, the fields of Medicinal Chemistry and especially the ones related to the so-called Personalized Medicine, have received a great attention. Significant investment and remarkable researches surround the matter; however, not all those promising advances are reaching patients as quickly as they should. The absence of an adequate regulatory framework could be of no help. The complete and/or massive sequencing of individual genomes faces many ethical-legal challenges. Some of them are access to Personalized Medicine; the treatment of a large volume of sensitive information and the use of tools produced by "big data" systems in clinical care or in predictive models. In addition, the legal protection of personal data related to health, the exercise of autonomy by patients, closely related to the regulation regarding clinical trials, are seriously involved. Our purpose of this work is to review the regulations of the European Union, in an attempt to contribute to a better understanding of the legal framework for the implementation and development of health systems based on Personalized Medicine.
Export Options
About this article
Cite this article as:
Duardo-Sánchez Aliuska *, De Miguel Beriain Iñigo , Personalized Medicine and Medicinal Chemistry: Toward a Legal Framework in the European Union, Current Topics in Medicinal Chemistry 2018; 18 (25) . https://dx.doi.org/10.2174/1568026619666181120144213
DOI https://dx.doi.org/10.2174/1568026619666181120144213 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complexities of TGF-β Action During Mammary and Squamous Cell Carcinogenesis
Current Pharmaceutical Biotechnology Chlorella vulgaris: A Multifunctional Dietary Supplement with Diverse Medicinal Properties
Current Pharmaceutical Design Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment
Current Signal Transduction Therapy Targeting Breast Cancer Stem Cells: A Methodological Perspective
Current Stem Cell Research & Therapy Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine The Epithelial-Mesenchymal Transition and the Estrogen-Signaling in Ovarian Cancer
Current Drug Targets Long-Term Safety from the Raltegravir Clinical Development Program
Current HIV Research Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in the Treatment of Breast Cancer: Recent Advances and Future Directions
Reviews on Recent Clinical Trials Erythropoietin and Oxidative Stress
Current Neurovascular Research Crystallization and X-Ray Data Analysis of the Extended Dna-Binding Domain of the E2 Bovine Papillomavirus Type 1 Protein
Protein & Peptide Letters Challenges in Oral Delivery: Role of P-gp Efflux Pump
Current Drug Therapy Nontoxic-dose of Deguelin Induce NPMc+ AML Cell Differentiation by Selectively Targeting Mt NPM1/SIRT1 Instead of HDAC1/3
Current Cancer Drug Targets HER-2 / neu and Topoisomerase IIα - Simultaneous Drug Targets in Cancer
Combinatorial Chemistry & High Throughput Screening Mediastinal Epithelioid Hemangioendothelioma Invading Superior Vena Cava: A Case Report and Review of Literature
Current Medical Imaging Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Sumoylation Pathway as Potential Therapeutic Targets in Cancer
Current Molecular Medicine Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism Modeling and Proposed Molecular Mechanism of Hydroxyurea Through Docking and Molecular Dynamic Simulation to Curtail the Action of Ribonucleotide Reductase
Recent Patents on Anti-Cancer Drug Discovery Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry